About US
Contact us
-
Teva's patent failure gives long-acting Copaxone generics free reinTeva's strategy for padding its Copaxone franchise even in the face of generic competition just took a major hit. The company lost its bid to defend the long-acting, 40mg version of the multiple scl2018/10/16
-
Neopharma snatches Dr. Reddy's API business as it continues global expansionJust weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business to the Middle2018/10/16
-
Is Bayer's first sell-off here? Animal health may be up for grabs as Monsanto weighs on pharmaWill Bayer heed the advice from investors and analysts and split up the conglomerate? New clues suggest it just might. The German company is weighing a sale of its animal health business as part of a2018/10/15
-
Actually, it's just one site: FDA corrects previous word on embattled valsartan maker's banAfter Zhejiang Huahai Pharmaceutical’s tainted valsartan API triggered a global recall, the FDA slapped an import ban on the drugmaker. But the agency made a confusing mistake in announcing the move—a2018/10/15
-
UCLH initiates new trial for Alzheimer’s treatment in UKThe NIHR University College London Hospitals (UCLH) Clinical Research Facility in the UK has initiated a clinical trial, DESPIAD, to assess a new treatment called miridesap for Alzheimer’s disease. S2018/10/12
-
Ionis partners with Roche to advance new antisense drugIonis Pharmaceuticals has entered a deal worth up to $760m with Roche for further development of its antisense drug, IONIS-FB-L, to treat complement-mediated diseases. IONIS-FB-L is designed using Io2018/10/12
-
Latin America’s medical cannabis market to reach $8.5bn by 2028Research consultancy Prohibition Partners has predicted that medical cannabis will account for approximately two-thirds of the total value of Latin America’s cannabis market by 2028 in its first Latin2018/10/11
-
Janssen reports positive data of Stelara drug from UNIFI trialJanssen Pharmaceutical has reported positive eight-week induction data from Phase III UNIFI clinical trial of Stelara (ustekinumab) for the treatment of adults with moderate to severe ulcera2018/10/11
-
The First FDA-approved Digital Pill — What It Means for PharmaLast year, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill that is integrated with an ingestible sensor that captures i2018/10/10
-
Litigation teaches Chinese valsartan maker the downside of U.S. marketChina’s Zhejiang Huahai Pharmaceutical for years enjoyed the upside of the U.S. pharmaceutical market, selling its valsartan API to drugmakers producingblood pressure meds for the market. Now it is se2018/10/10